单药替吉奥胶囊治疗老年晚期胃癌的临床观察

目的：观察单药替吉奥胶囊治疗晚期胃癌的临床疗效及毒副反应。方法：选择50例经病理证实的老年晚期胃癌患者，随机分为治疗组32例及对照组18例。治疗组根据体表面积给予替吉奥胶囊治疗，对照组给予营养等最佳支持治疗。每2周期后行影像学检查评价疗效、记录不良反应及随访情况。结果：治疗组32例患者CR(完全缓解)0例，PR(部分缓解)10例，SD(病情稳定)12例，PD(病情进展)10例，临床总缓解率31.3%，临床获益率68.8%。治疗组中位无疾病进展时间及中位生存期分别为5.7及11.5个月，对照组分别为3.1及7.6个月。毒副反应主要为I-III度骨髓抑制、消化道反应、肝功能损伤及手足综合症。结论：单药替吉奥胶囊治疗老年晚期胃癌效果肯定，生活质量高、毒副作用小。

Clinical observation of S-1 capsule in the treatment of elderly patients with advanced gastric cancer

Objective: To evaluate the efficiency and toxicities of S-1 capsule in the treatment of elderly patients with advanced gastric cancer.Methods: Fitfy elderly patients with advanced gastric cancer were divided into treatment group (32 cases) and control group (18 cases). Patients of treatment group were treated with S-1, patients of control group were given the best support treatment. After two consecutive treatment circles, the clinical effcacy, adverse effects and follow-up condition were evaluated.Results: In the treatment group, no case showed remission (CR), 10 cases showed partial remission (PR), 12 cases showed stable disease (SD), 10 cases showed progressive disease (PD). hTe responsive rate (CR + PR) was 31.3%, the illness control rate (CR + PR + SD) was 68.8%. The progression free survival (PFS) and median survival time (MST) in treatment group were 5.7 and 11.5 months respectively, and 3.1 and 7.6 months in the control group respectively. The major adverse events were myelosuppression ranging from grade I to III, disgusting damage of liver function and hand-foot syndrome. Conclusion: The S-1 shows a positive effect for elderly patients with advanced gastric cancer. It can achieve a better quality of life and small side effects for the patients.